Patent: 6,250,469
✉ Email this page to a colleague
Summary for Patent: 6,250,469
Title: | Formulations for protection of peg-interferon alpha conjugates |
Abstract: | The present invention provides formulations that prevent loss and damage of PEG-interferon alpha conjugates during and following lyophilization. The formulations of the present invention protect PEG-interferon alpha conjugates from loss and degradation during the lyophilization process, as well as degradation during subsequent storage. The formulations of the present invention are suitable for protection of PEG-interferon alpha conjugates from various types of degradation, including, but not limited to loss of biological activity and changes in the degree and/or nature of conjugation. A preferred PEG-interferon alpha conjugate protectable in the formulations of the present invention is an interferon alpha-2b-polyethylene glycol (12,000) conjugate. |
Inventor(s): | Kline; Douglas (New York, NY) |
Assignee: | Schering Corporation (Kenilworth, NJ) |
Application Number: | 09/703,581 |
Patent Claims: | see list of patent claims |
Details for Patent 6,250,469
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Merck Sharp & Dohme Corp. | PEGINTRON | peginterferon alfa-2b | Injection | 103949 | 01/19/2001 | ⤷ Try a Trial | 2018-03-26 |
Merck Sharp & Dohme Corp. | SYLATRON | peginterferon alfa-2b | For Injection | 103949 | 03/29/2011 | ⤷ Try a Trial | 2018-03-26 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
International Patent Family for US Patent 6,250,469
Country | Patent Number | Estimated Expiration |
---|---|---|
United States of America | 6180096 | ⤷ Try a Trial |
>Country | >Patent Number | >Estimated Expiration |